A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated and Relapsed Acute Myeloid Leukemia with an IDH1 Mutation Who Are Candidates for Non-intensive Therapy

Type of Cancer
Leukemia

Sponsor
Agios

Protocol Number
AG-120-C-009

To Learn More Call
201-510-0910

Individual Patient Supply of Oral Pacritinib in a Patient with Thrombocytopenia and Primary Myelofibrosis.

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Hackensack UMC

Protocol Number
Compassionate Use Pacritinib

To Learn More Call
201-510-0910

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Type of Cancer
Leukemia

Sponsor
Bristol-Myers Squibb

Protocol Number
CA 180-653

To Learn More Call
201-510-0910

INVESTIGATION OF BCR MUTATIONS WITHIN BCR-ABL IN PHILADELPHIA-POSITIVE LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
UMDNJ

Protocol Number
UMDNJ Sampling BCR Mutations

To Learn More Call
201-510-0910

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Sponsor
Incyte

Protocol Number
Incyte INCB 50465-201

To Learn More Call
201-510-0910

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
East Brunswick

Sponsor
Gilead

Protocol Number
GS-312-0118

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda